NASDAQ:ARWR Arrowhead Pharmaceuticals Stock Price, Forecast & News $32.01-.76 (-2.32 %) (As of 06/3/2020 04:00 PM ET) Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Zacks Investment Research Page 3 scr.zacks.com ethics approval, are awaiting regulatory feedback and are preparing to commence the study once approvals are granted. The study, expected to enroll up to 63 subjects, also has single and multiple dose phases and will be used to help inform subsequent development. Why Arrowhead Pharmaceuticals Shares Dropped 15% in February After a stellar 2019, the biotech stock has lost 47% so far in 2020. Zacks Investment Research Page 4 scr.zacks.com - 100mg of ARO-APOC3 was associated with 63% reduction in plasma triglycerides and 94% reduction in APOC3. Particularly noteworthy is the durability of this robust effect, which appears (see graphs below) to have remained at or near trough level through week 12. Zacks Investment Research Page 3 scr.zacks.com AAT sustained reduction of mutant Z-AAT protein1 JNJ-3989 EASL Presentation Also at EASL ILC ARWR presented interim results of JNJ-3989 (ARO-HBV) among 40 patients at 24+ weeks follow-up in their ongoing AROHBV1001 study. Zacks Projected EPS Growth Rate - Next 5 Years % N/A Zacks Small-Cap Research scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 8, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 ARWR: ANG3 Ph1 in Dyslipidemia Commences Relative valuation metrics indicates a fair value at $30/share. Zacks Investment Research Page 4 scr.zacks.com Dosing began in late March. The study, AROHBV1001 (NCT03365947), is a Phase I/II study to evaluate the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in healthy adult volunteers, and to
Arrowhead Pharmaceuticals (NASDAQ:ARWR)'s stock had its "buy" rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, AnalystRatings.com reports. They presently have a $58.00 target price on the biotechnology company's stock, down from their prior target price of $60.00. Cantor Fitzgerald's price target indicates a potential Barchart allows you to view options by Expiration Date (select the expiration month/year using the drop-down menu at the top of the page). Weekly expiration dates are labeled with a (w) in the expiration date list. Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by investment analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage currently has a $60.00 target price on the biotechnology company's stock, up from their previous target price of $55.00. The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. For the ARWR price target at the top of this page, we present the average ARWR target price across the 10 analysts covering ARWR, as reported in data provided by Zacks Investment Research via Quandl.com.The median ARWR price target (a different metric than the
Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports Roku, Inc. (ROKU): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Should I buy Arrowhead Pharmaceuticals, Inc. (ARWR)? Use the Zacks Rank and Style Scores to find out is ARWR is right for your portfolio. ARWR: Arrowhead Pharmaceuticals Inc options chain stock quote. Get the latest options chain stock quote information from Zacks Investment Research.
Arrowhead Pharmaceuticals - 23 Year Stock Price History | ARWR